SGMO Cash-Secured Put Strategy

SGMO (Sangamo Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine.

SGMO (Sangamo Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $58.4M, a beta of 1.04 versus the broader market, a 52-week range of 0.1-0.77, average daily share volume of 10.5M, a public-listing history dating back to 2000, approximately 183 full-time employees. These structural characteristics shape how SGMO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.04 places SGMO roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a cash-secured put on SGMO?

A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.

Current SGMO snapshot

As of May 15, 2026, spot at $1.50, ATM IV 21.50%, IV rank 1.44%, expected move 6.16%. The cash-secured put on SGMO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this cash-secured put structure on SGMO specifically: SGMO IV at 21.50% is on the cheap side of its 1-year range, which means a premium-selling SGMO cash-secured put collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 6.16% (roughly $0.09 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated SGMO expiries trade a higher absolute premium for lower per-day decay. Position sizing on SGMO should anchor to the underlying notional of $1.50 per share and to the trader's directional view on SGMO stock.

SGMO cash-secured put setup

The SGMO cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With SGMO near $1.50, the first option leg uses a $1.42 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed SGMO chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 SGMO shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Sell 1Put$1.42N/A

SGMO cash-secured put risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.

SGMO cash-secured put payoff curve

Modeled P&L at expiration across a range of underlying prices for the cash-secured put on SGMO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use cash-secured put on SGMO

Cash-secured puts on SGMO earn premium while a trader waits to acquire SGMO stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning SGMO.

SGMO thesis for this cash-secured put

The market-implied 1-standard-deviation range for SGMO extends from approximately $1.41 on the downside to $1.59 on the upside. A SGMO cash-secured put lets a trader earn premium while waiting to acquire SGMO at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current SGMO IV rank near 1.44% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on SGMO at 21.50%. As a Healthcare name, SGMO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to SGMO-specific events.

SGMO cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. SGMO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move SGMO alongside the broader basket even when SGMO-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on SGMO carry tail risk when realized volatility exceeds the implied move; review historical SGMO earnings reactions and macro stress periods before sizing. Always rebuild the position from current SGMO chain quotes before placing a trade.

Frequently asked questions

What is a cash-secured put on SGMO?
A cash-secured put on SGMO is the cash-secured put strategy applied to SGMO (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With SGMO stock trading near $1.50, the strikes shown on this page are snapped to the nearest listed SGMO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are SGMO cash-secured put max profit and max loss calculated?
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the SGMO cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 21.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a SGMO cash-secured put?
The breakeven for the SGMO cash-secured put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current SGMO market-implied 1-standard-deviation expected move is approximately 6.16%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a cash-secured put on SGMO?
Cash-secured puts on SGMO earn premium while a trader waits to acquire SGMO stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning SGMO.
How does current SGMO implied volatility affect this cash-secured put?
SGMO ATM IV is at 21.50% with IV rank near 1.44%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related SGMO analysis